|
1
|
Samai M, Seward JF, Goldstein ST, Mahon BE, Lisk DR, Widdowson MA, Jalloh MI, Schrag SJ, Idriss A, Carter RJ, Dawson P, Kargbo SAS, Leigh B, Bawoh M, Legardy-Williams J, Deen G, Carr W, Callis A, Lindblad R, Russell JBW, Petrie CR, Fombah AE, Kargbo B, McDonald W, Jarrett OD, Walker RE, Gargiullo P, Bash-Taqi D, Gibson L, Fofanah AB, Schuchat A. The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSV∆G-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak. J Infect Dis 2019; 217:S6-S15. [PMID: 29788345 DOI: 10.1093/infdis/jiy020] [Citation(s) in RCA: 57] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Clinical Trials Registration ClinicalTrials.gov [NCT02378753] and Pan African Clinical Trials Registry [PACTR201502001037220].
Collapse
Affiliation(s)
- Mohamed Samai
- College of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone
| | - Jane F Seward
- College of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone
| | | | - Barbara E Mahon
- Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | | | - Mohamed I Jalloh
- College of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone
| | | | - Ayesha Idriss
- College of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone
| | | | | | - S A S Kargbo
- College of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone
| | - Bailah Leigh
- College of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone
| | - Mohamed Bawoh
- College of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone
| | | | - Gibrilla Deen
- College of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone
| | - Wendy Carr
- Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Amy Callis
- Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | - James B W Russell
- College of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone
| | | | - Augustin E Fombah
- College of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone
| | | | - Wendi McDonald
- College of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone
| | - Olamide D Jarrett
- College of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone
| | - Robert E Walker
- Biomedical Advanced Research and Development Authority, Department of Health and Human Services, Washington, DC
| | - Paul Gargiullo
- Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Donald Bash-Taqi
- College of Medicine and Allied Health Sciences, University of Freetown, Sierra Leone
| | - Laura Gibson
- Biomedical Advanced Research and Development Authority, Department of Health and Human Services, Washington, DC
| | | | - Anne Schuchat
- Centers for Disease Control and Prevention, Atlanta, Georgia
| | | |
Collapse
|
|
2
|
Jusu MO, Glauser G, Seward JF, Bawoh M, Tempel J, Friend M, Littlefield D, Lahai M, Jalloh HM, Sesay AB, Caulker AF, Samai M, Thomas V, Farrell N, Widdowson MA. Rapid Establishment of a Cold Chain Capacity of -60°C or Colder for the STRIVE Ebola Vaccine Trial During the Ebola Outbreak in Sierra Leone. J Infect Dis 2019; 217:S48-S55. [PMID: 29788339 DOI: 10.1093/infdis/jix336] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Clinical Trials Registration ClinicalTrials.gov [NCT02378753] and Pan African Clinical Trials Registry [PACTR201502001037220].
Collapse
Affiliation(s)
- Morrison O Jusu
- College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone
| | | | - Jane F Seward
- Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Mohamed Bawoh
- College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone
| | | | - Michael Friend
- Global Good, Intellectual Ventures, Bellevue, Washington
| | | | - Michael Lahai
- College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone
| | - Hassan M Jalloh
- College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone
| | - Amara Bangali Sesay
- College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone
| | - Amanda F Caulker
- College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone
| | - Mohamed Samai
- College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone
| | - Vasavi Thomas
- Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | | |
Collapse
|
|
3
|
Kis Z, Papathanasiou M, Calvo‐Serrano R, Kontoravdi C, Shah N. A model‐based quantification of the impact of new manufacturing technologies on developing country vaccine supply chain performance: A Kenyan case study. ACTA ACUST UNITED AC 2019. [DOI: 10.1002/amp2.10025] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Zoltán Kis
- Center for Process Systems Engineering, Department of Chemical Engineering, Faculty of EngineeringImperial College London London UK
| | - Maria Papathanasiou
- Center for Process Systems Engineering, Department of Chemical Engineering, Faculty of EngineeringImperial College London London UK
| | - Raul Calvo‐Serrano
- Center for Process Systems Engineering, Department of Chemical Engineering, Faculty of EngineeringImperial College London London UK
| | - Cleo Kontoravdi
- Center for Process Systems Engineering, Department of Chemical Engineering, Faculty of EngineeringImperial College London London UK
| | - Nilay Shah
- Center for Process Systems Engineering, Department of Chemical Engineering, Faculty of EngineeringImperial College London London UK
| |
Collapse
|
|
4
|
Abstract
The recent outbreak of Ebola virus disease in West Africa has led to more than 11,000 deaths, with a peak in mortality from August through December of 2014. A meeting convened by the World Health Organization (WHO) in September 2014, concluded that an urgent unmet need exists for efficacy and safety testing of the Ebola virus vaccine candidates and that clinical trials should be expedited. These vaccines could be used both in an outbreak setting and to provide long-term protection in populations at risk of sporadic outbreaks. A number of vaccines have been evaluated in phase 1 trials, but the two most advanced first-generation Ebola vaccine candidates are the live replicating vesicular stomatitis virus (rVSV) and the replication-defective chimpanzee adenovirus 3 (ChAd3). This review focuses on these two vaccines in clinical development and discusses the future opportunities and challenges faced in the licensure and deployment of Ebola virus vaccines.
Collapse
Affiliation(s)
- Vincent Pavot
- The Jenner Institute, University of Oxford, Oxford, UK
| |
Collapse
|